Revive Therapeutics Doubles Bought Deal Financing To $20.0 Million
Revive Therapeutics (CSE: RVV) has upsized the bought deal financing announced last night. Originally pegged at $10.0 million in gross
Read moreRevive Therapeutics (CSE: RVV) has upsized the bought deal financing announced last night. Originally pegged at $10.0 million in gross
Read moreRevive Therapeutics (CSE: RVV) this evening announced that it will be conducting a bought deal financing, lead by Leede Jones
Read moreRevive Therapeutics (CSE: RVV) this morning announced that it has entered into a sponsored research collaboration agreement, as well as
Read moreRevive Therapeutics (CSE: RVV) has strengthened its scientific and advisory team as it looks to close out the year. Dr
Read moreRevive Therapeutics (CSE: RVV) issued an update to the market this morning related to its phase 3 clinical trial for
Read moreRevive Therapeutics (CSE: RVV) this morning announced that it has entered into a letter of intent to acquire PharmaTher Inc’s
Read moreFor our final episode of The Daily Dive this week, host Cassandra Leah is joined by that of Derek Welsh
Read moreRevive Therapeutics (CSE: RVV) and Pharmather Inc (CSE: PHRM) this morning jointly announced a research collaboration between the two firms.
Read moreRevive Therapeutics (CSE: RVV) has completed its oral thin film strip product for psilocybin after several months of prototyping. The
Read moreRevive Therapeutics (CSE: RVV) provided an update on the status of its ongoing phase three clinical trials for the evaluation
Read more